We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
+11.53%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$1.52B
AUM Growth
-$155M
(-9.3%)
Cap. Flow
-$217M
Cap. Flow
% of AUM
-14.3%
Top 10 Holdings %
Top 10 Hldgs %
51.8%
Holding
41
New
7
Increased
5
Reduced
10
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$97.4M |
| 2 |
DaVita
DVA
|
+$44.6M |
| 3 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$44.6M |
| 4 |
DexCom
DXCM
|
+$44.2M |
| 5 |
Viasat
VSAT
|
+$33.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.9M |
| 2 |
AET
Aetna Inc
AET
|
+$61.4M |
| 3 |
AGN
Allergan plc
AGN
|
+$58.6M |
| 4 |
Merck
MRK
|
+$50.4M |
| 5 |
Ironwood Pharmaceuticals
IRWD
|
+$40.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 45.53% |
| 2 | Consumer Discretionary | 12.98% |
| 3 | Technology | 10.14% |
| 4 | Communication Services | 6.8% |
| 5 | Consumer Staples | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PVG
26
DELISTED
PRETIUM RESOURCES INC.
PVG
| $18.8M | 1.24% |
1,651,328
| – | – |
|
27
Chipotle Mexican Grill
CMG
$47.8B
| $16.1M | 1.06% |
2,785,800
| – | – |
|
28
VeriSign
VRSN
$26.2B
| $15.3M | 1.01% |
133,456
-183,541
| -58% | -$20.5M |
|
29
Teva Pharmaceuticals
TEVA
$40.9B
| $14.2M | 0.94% |
750,000
| – | – |
|
30
Wave Life Sciences
WVE
$1.09B
| $11.9M | 0.78% |
337,949
+47,064
| +16% | +$1.37M |
|
31
Zimmer Biomet
ZBH
$18.1B
| $11.3M | 0.75% |
96,748
-350,187
| -78% | -$39.6M |
|
|
DRNA
32
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $8.18M | 0.54% |
+905,998
| New | +$6.67M |
|
33
Denali Therapeutics
DNLI
$3.68B
| $4.89M | 0.32% |
+312,500
| New | +$5.62M |
|
|
34
Ironwood Pharmaceuticals
IRWD
$686M
| – | – |
-3,040,037
| Closed | -$40.2M |
|
35
Molina Healthcare
MOH
$10.2B
| – | – |
-413,347
| Closed | -$28.4M |
|
|
36
Merck
MRK
$323B
| – | – |
-825,297
| Closed | -$50.4M |
|
37
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
| – | – |
-721,000
| Closed | -$62.4M |
|
|
ALXN
38
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-555,120
| Closed | -$77.9M |
|
|
AGN
39
DELISTED
Allergan plc
AGN
| – | – |
-286,002
| Closed | -$58.6M |
|
|
AET
40
DELISTED
Aetna Inc
AET
| – | – |
-386,100
| Closed | -$61.4M |
|
|
IPXL
41
DELISTED
Impax Laboratories, Inc.
IPXL
| – | – |
-602,456
| Closed | -$12.2M |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q4 2017 Portfolio in Review
As of Q4 2017, Bridger Management held 41 positions worth $1.52B, down 9.3% from $1.67B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Bridger Management withdrew a net $217M in Q4 2017, closing 8 positions and reducing 10 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $77.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Bridger Management opened a new position in Labcorp worth $101M.
- Bridger Management's largest Q4 2017 buy was Labcorp: 737,001 shares worth $101M.
- Bridger Management added most to Incyte in Q4 2017, an estimated $32.1M increase.
- Bridger Management's biggest Q4 2017 reduction was Zimmer Biomet, cutting an estimated $39.6M.
- Bridger Management fully exited Alexion Pharmaceuticals in Q4 2017, selling an estimated $77.9M.
- Bridger Management's ten largest holdings make up 52% of its $1.52B portfolio in Q4 2017.
- Bridger Management opened 7 new positions and closed 8 in Q4 2017.
- Bridger Management's portfolio value fell 9.3% quarter-over-quarter to $1.52B.
Based on Bridger Management's 13F filing for Q4 2017, filed 14 Feb 2018.